Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 317, doi. 10.1002/pst.1856
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2018 AND VI 17 AND IP 4
Results: 9
1
2
BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 383, doi. 10.1002/pst.1864
- By:
- Publication type:
- Article
3
How to use prior knowledge and still give new data a chance?
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 329, doi. 10.1002/pst.1862
- By:
- Publication type:
- Article
4
Bayesian applications in pharmaceutical statistics.
- Published in:
- 2018
- By:
- Publication type:
- Editorial
5
Better decision making in drug development through adoption of formal prior elicitation.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 301, doi. 10.1002/pst.1854
- By:
- Publication type:
- Article
6
Bayesian statistical models to estimate EQ‐5D utility scores from EORTC QLQ data in myeloma.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 358, doi. 10.1002/pst.1853
- By:
- Publication type:
- Article
7
Bayesian approach for assessing noninferiority in a three‐arm trial with binary endpoint.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 342, doi. 10.1002/pst.1851
- By:
- Publication type:
- Article
8
Bayesian dose‐finding phase I trial design incorporating historical data from a preceding trial.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 372, doi. 10.1002/pst.1850
- By:
- Publication type:
- Article
9
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 4, p. 295, doi. 10.1002/pst.1827
- Publication type:
- Article